NCT06059287View on ClinicalTrials.gov

The Effect of Henagliflozin and Metformin on Myocardial Tissue-level Characteristics

NANot yet recruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
ObesityType 2 DiabetesSodium-glucose Co-transporter-2 InhibitorMyocardial FibrosisMagnetic Resonance Imaging
Interventions
DRUG

Henagliflozin

Henagliflozin 10mg qd po

DRUG

Metformin

Metformin 1000mg bid po

All Listed Sponsors
lead

RenJi Hospital

OTHER

NCT06059287 - The Effect of Henagliflozin and Metformin on Myocardial Tissue-level Characteristics | Biotech Hunter | Biotech Hunter